Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the World Heart Federation
By: Álvaro Sosa Liprandi, María Inés Sosa Liprandi, Ezequiel José Zaidel, Gabriel M. Aisenberg, Adrián Baranchuk, Eduardo Costa Duarte Barbosa, Gabriela Borrayo Sánchez, Bryce Alexander, Fernando Tomás Lanas Zanetti, Ricardo López Santi, Ana Girleza Múnera-Echeverri, Pablo Perel, Daniel Piskorz, Carlos Enrique Ruiz-Mori, Jorge Saucedo, Osiris Valdez, José Ramón González Juanatey, Daniel José Piñeiro, Fausto J. Pinto and Fernando Stuardo Wyss Quintana
References
- GBD Compare|IHME Viz Hub.
http://vizhub.healthdata.org/gbd-compare (Accessed Jan 16, 2021). - Warren-Gash C, Smeeth L, Ayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. Lancet Infect Dis. 2009; 9: 601–10. DOI: 10.1016/S1473-3099(09)70233-6
- Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010 Feb; 10(2): 83–92. DOI: 10.1016/S1473-3099(09)70331-7
- Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza and cardiovascular disease: Is there a causal relationship? Tex Heart Inst J. 2004; 31(1): 4–13.
- Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: Case-control study through a general practice database. Eur Heart J. 2007 Dec 8; 29(1): 96–103. DOI: 10.1093/eurheartj/ehm516
- Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet Lond Engl. 1998 May 16; 351(9114): 1467–71. DOI: 10.1016/S0140-6736(97)11084-4
- Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: Prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984 Feb 1; 53(4): 481–2. DOI: 10.1016/0002-9149(84)90016-X
- Clayton TC, Capps NE, Stephens NG, Wedzicha JA, Meade TW. Recent respiratory infection and the risk of myocardial infarction. Heart Br Card Soc. 2005 Dec; 91(12): 1601–2. DOI: 10.1136/hrt.2004.046920
- Mattila KJ. Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med. 1989 May; 225(5): 293–6. DOI: 10.1111/j.1365-2796.1989.tb00084.x
- Abinader EG, Sharif DS, Omary M. Inferior wall myocardial infarction preceded by acute exudative pharyngitis in young males. Isr J Med Sci. 1993 Dec; 29(12): 764–9.
- Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction. J Am Coll Cardiol. 1998 May; 31(6): 1226–33. DOI: 10.1016/S0735-1097(98)00098-9
- Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et al. Influenza vaccination in patients with chronic heart failure: The PARADIGM-HF trial. JACC Heart Fail. 2016 Feb; 4(2): 152–8. DOI: 10.1016/j.jchf.2015.10.012
- Zaidel EJ, Cacia SL, Pérez GE, Costabel JP, Failo M, Rosende A, et al. Vacuna antineumocócica en adultos: Encuesta a residentes de cardiología de argentina. Rev CONAREC. 2014; 15: 101–104.
http://www.revistaconarec.com.ar/contenido/art.php?recordID=MTA0Mw== . - Martins W de A, Ribeiro MD, Oliveira LB de, Barros L da SN de, Jorge AC da SM, Santos CM dos, et al. Influenza and pneumococcal vaccination in heart failure: A little applied recommendation. Arq Bras Cardiol. 2011 Mar; 96(3): 240–5. DOI: 10.1016/S0048-7120(01)73220-3
- Amuedo ME, Vargas MC. Métodos de consenso. Uso adecuado de la evidencia en la toma de decisiones. “Método RAND/UCLA”. Rehabilitación. 2001 Dec 31; 35: 388–92.
- Fitch K (ed.). The Rand/UCLA appropriateness method user’s manual. Santa Monica: Rand; 2001. 109 p.
- SIAC|GUÍAS|SIAC.
http://www.siacardio.com/category/educacion/guias/ (Accessed Mar 28, 2021). - Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25; 73(24): 3168–209.
- Kwok CS, Aslam S, Kontopantelis E, Myint PK, Zaman MJS, Buchan I, et al. Influenza, influenza-like symptoms and their association with cardiovascular risks: A systematic review and meta-analysis of observational studies. Int J Clin Pract. 2015 Sep; 69(9): 928–37. DOI: 10.1111/ijcp.12646
- Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: Results from 8 years of autopsies in 34 892 subjects. Eur Heart J. 2007 May 1; 28(10): 1205–10. DOI: 10.1093/eurheartj/ehm035
- Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25; 378(4): 345–53. DOI: 10.1056/NEJMoa1702090
- Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: A self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018 Mar 1; 51(3).
https://erj.ersjournals.com/content/51/3/1701794 . DOI: 10.1183/13993003.01794-2017 - Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965 May; 58(5): 295–300. DOI: 10.1177/003591576505800503
- Chang T-Y, Chao T-F, Liu C-J, Chen S-J, Chung F-P, Liao J-N, et al. The association between influenza infection, vaccination, and atrial fibrillation: A nationwide case-control study. Heart Rhythm. 2016 Jun 1; 13(6): 1189–94. DOI: 10.1016/j.hrthm.2016.01.026
- Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, et al. Association of Influenza-like Illness Activity with Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2019 Apr 1; 4(4): 363–9. DOI: 10.1001/jamacardio.2019.0549
- Panhwar MS, Kalra A, Gupta T, Kolte D, Khera S, Bhatt DL, et al. Effect of Influenza on Outcomes in Patients with Heart Failure. JACC Heart Fail. 2019 Feb 1; 7(2): 112–7. DOI: 10.1016/j.jchf.2018.10.011
- van Wissen M, Keller TT, Ronkes B, Gerdes VE, Zaaijer HL, van Gorp EC, et al. Influenza infection and risk of acute pulmonary embolism. Thromb J. 2007 Oct 16; 5(1): 16. DOI: 10.1186/1477-9560-5-16
- Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 Influenza Infection and Vascular Thrombosis. Clin Infect Dis. 2011 Jan 15; 52(2): e14–7. DOI: 10.1093/cid/ciq125
- Avnon LS, Munteanu D, Smoliakov A, Jotkowitz A, Barski L. Thromboembolic events in patients with severe pandemic influenza A/H1N1. Eur J Intern Med. 2015 Oct; 26(8): 596–8. DOI: 10.1016/j.ejim.2015.08.017
- Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection – Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009 Jul 17; 58(27): 749–52.
- Zhu T, Carcaillon L, Martinez I, Cambou J-P, Kyndt X, Guillot K, et al. Association of influenza vaccination with reduced risk of venous thromboembolism. Thromb Haemost. 2009 Dec; 102(6): 1259–64. DOI: 10.1160/TH09-04-0222
- Pearce DC, McCaw JM, McVernon J, Mathews JD. Influenza as a trigger for cardiovascular disease: An investigation of serotype, subtype and geographic location. Environ Res. 2017 Jul; 156: 688–96. DOI: 10.1016/j.envres.2017.04.024
- Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959–1999. Am J Epidemiol. 2004 Sep 1; 160(5): 492–502. DOI: 10.1093/aje/kwh227
- Lichenstein R, Magder LS, King RE, King JC. The relationship between influenza outbreaks and acute ischemic heart disease in Maryland residents over a 7-year period. J Infect Dis. 2012 Sep 15; 206(6): 821–7. DOI: 10.1093/infdis/jis435
- Gurevich VS, Pleskov VM, Levaia MV, Bannikov AI, Mitrofanova LB, Urazgil’deeva SA. Influenza virus infection in progressing atherosclerosis. Kardiologiia. 2002; 42(7): 21–4.
- Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and Myocardial Infarction. N Engl J Med. 2019 Jan 10; 380(2): 171–6. DOI: 10.1056/NEJMra1808137
- Finelli L, Chaves SS. Influenza and acute myocardial infarction. J Infect Dis. 2011 Jun 15; 203(12): 1701–4. DOI: 10.1093/infdis/jir175
- McCarthy Z, Xu S, Rahman A, Bragazzi NL, Corrales-Medina VF, Lee J, et al. Modelling the linkage between influenza infection and cardiovascular events via thrombosis. Sci Rep. 2020 Aug 31; 10(1): 14264. DOI: 10.1038/s41598-020-70753-0
- Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engstrøm T, et al. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189: 94–102. DOI: 10.1016/j.ahj.2017.04.003
- LeBras MH, Barry AR. Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review. Can J Hosp Pharm. 2017 Feb; 70(1): 27–34. DOI: 10.4212/cjhp.v70i1.1626
- Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 May 7; 105(18): 2143–7. DOI: 10.1161/01.CIR.0000016182.85461.F4
- Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008 Jun; 29(11): 1350–8. DOI: 10.1161/01.CIR.0000016182.85461.F4
- Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul; 32(14): 1730–5. DOI: 10.1093/eurheartj/ehr004
- Shahid Beheshti University of Medical Sciences. Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris [Internet]. clinicaltrials.gov; 2009 Jan [cited 2021 Mar 26]. Report No.: NCT00607178. Available from:
https://clinicaltrials.gov/ct2/show/NCT00607178 - Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis. JAMA. 2013 Oct 23; 310(16): 1711–20. DOI: 10.1001/jama.2013.279206
- Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015 May 5; 5: CD005050. DOI: 10.1002/14651858.CD005050.pub3
- Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2021 Mar 16; 10(6):
e019636 . DOI: 10.1161/JAHA.120.019636 - Wu W-C, Jiang L, Friedmann PD, Trivedi A. Association between process quality measures for heart failure and mortality among US veterans. Am Heart J. 2014 Nov; 168(5): 713–20. DOI: 10.1016/j.ahj.2014.06.024
- Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: A self-controlled case series study. Eur Heart J. 2017 Feb 1; 38(5): 326–33.
- Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, et al. Influenza Vaccine in Heart Failure. Circulation. 2019 Jan 29; 139(5): 575–86. DOI: 10.1161/CIRCULATIONAHA.118.036788
- Rodrigues BS, David C, Costa J, Ferreira JJ, Pinto FJ, Caldeira D. Influenza vaccination in patients with heart failure: A systematic review and meta-analysis of observational studies. Heart Br Card Soc. 2020 Mar; 106(5): 350–7. DOI: 10.1136/heartjnl-2019-315193
- Loeb M, Dokainish H, Dans A, Palileo-Villanueva LM, Roy A, Karaye K, et al. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. Am Heart J. 2019 Jun; 212: 36–44. DOI: 10.1016/j.ahj.2019.02.009
- Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: Systematic review and meta-analysis. BMC Med. 2015 Mar 17; 13(1): 53. DOI: 10.1186/s12916-015-0295-6
- The flu vaccine and mortality in hypertension. A Danish nationwide cohort study.
https://esc365.escardio.org/Congress/195110-the-flu-vaccine-and-mortality-in-hypertension-a-danish-nationwide-cohort-study (Accessed Jan 16, 2021). - Kao P-F, Liu J-C, Hsu Y-P, Sung L-C, Yang T-Y, Hao W-R, et al. Influenza vaccination might reduce the risk of ischemic stroke in patients with atrial fibrillation: A population-based cohort study. Oncotarget. 2017 Dec 22; 8(68): 112697–711. DOI: 10.18632/oncotarget.22352
- Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2002 Apr 12; 51(RR-3): 1–31.
- Nichol KL. Influenza vaccination in the elderly: Impact on hospitalisation and mortality. Drugs Aging. 2005; 22(6): 495–515. DOI: 10.2165/00002512-200522060-00004
- Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke among the Elderly. N Engl J Med. 2003 Apr 3; 348(14): 1322–32. DOI: 10.1056/NEJMoa025028
- Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly. N Engl J Med. 2007 Oct 4; 357(14): 1373–81. DOI: 10.1056/NEJMoa070844
- Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994 Sep 22; 331(12): 778–84. DOI: 10.1056/NEJM199409223311206
- Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: National Academies Press; 2012.
http://www.nap.edu/catalog/13164 (Accessed Jan 16, 2021). - Petráš M, Lesná IK, Dáňová J, Čelko AM. Is an Increased Risk of Developing Guillain-Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis. Vaccines. 2020 Mar 27; 8(2). DOI: 10.3390/vaccines8020150
- Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet Lond Engl. 2013 Apr 27; 381(9876): 1461–8. DOI: 10.1016/S0140-6736(12)62189-8
- Moro PL, Woo EJ, Marquez P, Cano M. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011–2019. Vaccine. 2020 Aug 18; 38(37): 5923–6. DOI: 10.1016/j.vaccine.2020.07.007
- Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015. Vaccine. 2016 May 11; 34(22): 2507–12. DOI: 10.1016/j.vaccine.2016.03.048
- Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, et al. Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2015 Jun 18; 20(24). DOI: 10.2807/1560-7917.ES2015.20.24.21159
- Lee KR, Bae JH, Hwang IC, Kim KK, Suh HS, Ko KD. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017; 48(3–4): 103–10. DOI: 10.1159/000478017
- Kamath A, Maity N, Nayak MA. Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database. Clin Drug Investig. 2020 Sep 1; 40(9): 883–9. DOI: 10.1007/s40261-020-00952-0
- Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004 Feb 26; 350(9): 896–903. DOI: 10.1056/NEJMoa030595
- Stowe J, Andrews N, Wise L, Miller E. Bell’s palsy and parenteral inactivated influenza vaccine. Hum Vaccin. 2006 Jun; 2(3): 110–2. DOI: 10.4161/hv.2790
- Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M. Safety of live attenuated influenza vaccine in young people with egg allergy: Multicentre prospective cohort study. BMJ. 2015 Dec 8; h6291. DOI: 10.1136/bmj.h6291
- Rouleau I, De Serres G, Skowronski DM, Drolet JP, Lemire C, Toth E, et al. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine. 2014 Jun 12; 32(28): 3480–7. DOI: 10.1016/j.vaccine.2014.04.059
- Hayase Y, Tobita K. Influenza virus and neurological diseases. Psychiatry Clin Neurosci. 1997 Aug; 51(4): 181–4. DOI: 10.1111/j.1440-1819.1997.tb02580.x
- Cárdenas G, Soto-Hernández JL, Díaz-Alba A, Ugalde Y, Mérida-Puga J, Rosetti M, et al. Neurological events related to influenza A (H1N1) pdm09. Influenza Other Respir Viruses. 2014 May; 8(3): 339–46. DOI: 10.1111/irv.12241
- Ludvigsson JF, Winell H, Sandin S, Cnattingius S, Stephansson O, Pasternak B. Maternal Influenza A(H1N1) Immunization During Pregnancy and Risk for Autism Spectrum Disorder in Offspring: A Cohort Study. Ann Intern Med. 2020 Oct 20; 173(8): 597–604. DOI: 10.7326/M20-0167
- Mitkus RJ, King DB, Walderhaug MO, Forshee RA. A Comparative Pharmacokinetic Estimate of Mercury in U.S. Infants Following Yearly Exposures to Inactivated Influenza Vaccines Containing Thimerosal. Risk Anal. 2014; 34(4): 735–50. DOI: 10.1111/risa.12124
- Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015 Aug 7; 64(30): 818–25. DOI: 10.15585/mmwr.mm6430a3
- Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009 Sep 15; 339: b3680. DOI: 10.1136/bmj.b3680
- Greenhawt MJ, Spergel JM, Rank MA, Green TD, Mansoor D, Sharma H, Bird JA, Chang JE, Parikh DS, Teich E, Kelso JM, Sanders GM. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol. 2012 Dec; 109(6): 426–30. DOI: 10.1016/j.anai.2012.09.011
- McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, Hambidge SJ, Lee GM, Jackson LA, Irving SA, King JP, Kharbanda EO, Bednarczyk RA, DeStefano F. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar; 137(3): 868–78. DOI: 10.1016/j.jaci.2015.07.048
- Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013–May 31, 2015. Vaccine. 2016 May 11; 34(22): 2507–12. Epub 2016 Mar 23. PMID: 27015735; PMCID: PMC4916262. DOI: 10.1016/j.vaccine.2016.03.048
- García-Zamora S, Sosa Liprandi MI, Picco JM, Matta MG, Villarreal R, Pulido L, et al. Inmunizaciones en adultos con cardiopatías. Resumen del Consenso de la Sociedad Argentina de Cardiología [Immunizations in adults with cardiovascular disease. Summary of the Consensus of the Argentine Cardiology Society]. Medicina (B Aires). 2020; 80(5): 541–553. Spanish.
- Marra F, Young F, Richardson K, Marra CA. A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses. 2013 Jul; 7(4): 584–603. DOI: 10.1111/irv.12000
- Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. J Clin Pharm Ther. 2012 Oct; 37(5): 505–9. DOI: 10.1111/j.1365-2710.2012.01341.x
- Hesse EM, Navarro RA, Daley MF, Getahun D, Henninger ML, Jackson LA, et al. Risk for Subdeltoid Bursitis After Influenza Vaccination. Ann Intern Med. 2020 Jun 23; 173(4): 253–61. DOI: 10.7326/M19-3176
- Drug Interactions. Drugs.com.
https://www.drugs.com/interaction/list/?drug_list=243-0,3227-0 (Accessed Jan 16, 2021). - Morens DM, Halsey NA, Schonberger LB, Baublis JV. Reye syndrome associated with vaccination with live virus vaccines. An exploration of possible etiologic relationships. Clin Pediatr (Phila). 1979 Jan; 18(1): 42–4. DOI: 10.1177/000992287901800105
- Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010 Jan 15; 50(2): 175–83. DOI: 10.1086/649208
- Yin M, Huang L, Zhang Y, Yu N, Xu X, Liang Y, et al. Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: a meta-analysis. Expert Rev Vaccines. 2018 Jul; 17(7): 653–63. DOI: 10.1080/14760584.2018.1495077
- Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. Clin Exp Vaccine Res. 2017 Jan; 6(1): 38–44. DOI: 10.7774/cevr.2017.6.1.38
- vacunacion_2021.pdf.
https://www.aamr.org.ar/secciones/coronavirus/vacunacion_2021.pdf (Accessed Mar 26, 2021). - Seguridad de la vacuna contra la influenza estacional: Un resumen para médicos|CDC. 2020.
https://espanol.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm (Accessed Jan 16, 2021). - Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, et al. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients with High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021 Jan 5; 325(1): 39–49. DOI: 10.1001/jama.2020.23649
- Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccines Immunother. 2018 Mar 4; 14(3): 550–64. DOI: 10.1080/21645515.2017.1415684
- Soema PC, Kompier R, Amorij J-P, Kersten GFA. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2015 Aug; 94: 251–63. DOI: 10.1016/j.ejpb.2015.05.023
- Manzoli L, De Vito C, Salanti G, D’Addario M, Villari P, Ioannidis JPA. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PloS One. 2011; 6(9):
e24384 . DOI: 10.1371/journal.pone.0024384 - Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HKB, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008 Mar 1; 197(5): 667–75. DOI: 10.1086/527489
- Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013 Dec; 31(51): 6122–8. DOI: 10.1016/j.vaccine.2013.07.059
- Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine. 2011 Nov 3; 29(47): 8696–704. DOI: 10.1016/j.vaccine.2011.08.111
- Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, et al. Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. Pediatr Infect Dis J. 2009 Jul; 28(7): 563–71. DOI: 10.1097/INF.0b013e31819d6394
- Schwarz TF, Horacek T, Knuf M, Damman H-G, Roman F, Dramé M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine. 2009 Oct; 27(45): 6284–90. DOI: 10.1016/j.vaccine.2009.01.040
- McElhaney JE, Beran J, Devaster J-M, Esen M, Launay O, Leroux-Roels G, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013 Jun; 13(6): 485–96. DOI: 10.1016/S1473-3099(13)70046-X
- Durier C, Desaint C, Lucht F, Girard P-M, Lévy Y, May T, et al. Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03A adjuvant in HIV-1-infected adults. AIDS. 2013 Jan; 27(1): 87–93. DOI: 10.1097/QAD.0b013e328359f27a
- Rimmelzwaan G. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines. Vaccine. 2000 Dec; 19(9–10): 1180–7. DOI: 10.1016/S0264-410X(00)00310-8
- Fries LF, Smith GE, Glenn GM. A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine. N Engl J Med. 2013 Dec 26; 369(26): 2564–6. DOI: 10.1056/NEJMc1313186
- Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010 Dec; 28(52): 8268–74. DOI: 10.1016/j.vaccine.2010.10.009
- Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine. 2012 Aug; 30(39): 5761–9. DOI: 10.1016/j.vaccine.2012.06.086
- Diaz Granados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. N Engl J Med. 2014 Aug 14; 371(7): 635–45. DOI: 10.1056/NEJMoa1315727
- van Aalst R, Russo EM, Neupane N, Mahmud SM, Wilschut J, Samson SI, Chit A, Postma M, Young-Xu Y. Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method. Vaccine. 2021 Mar 15; 39(Suppl 1): A51–A55. DOI: 10.1016/j.vaccine.2020.05.080
- Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine. 2021 Mar 15; 39(Suppl 1): A24–A35. DOI: 10.1016/j.vaccine.2020.09.004
- Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine. 2017 May; 35(21): 2775–80. DOI: 10.1016/j.vaccine.2017.03.092
- Bhatt AS, Vardeny O, Udell JA, et al. Influenza vaccination: A ‘shot’ at INVESTing in cardiovascular health. European Heart Journal. 2021; 1–4.
- Patel MM, Uyeki TM. Influenza Vaccine for Patients with High-risk Cardiovascular Disease. JAMA. 2021 Jan 5; 325(1): 33–35. DOI: 10.1001/jama.2020.23948
- Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season. MMWR Recomm Rep. 2020; 69.
https://www.cdc.gov/mmwr/volumes/69/rr/rr6908a1.htm (Accessed Jan 17, 2021). DOI: 10.15585/mmwr.rr6908a1 - Shasha D, Valinsky L, Hershkowitz Sikron F, Glatman-Freedman A, Mandelboim M, Toledano A, et al. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study. Clin Microbiol Infect. 2020 Jan; 26(1): 101–6. DOI: 10.1016/j.cmi.2019.05.003
- Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, et al. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. Fast PE, (ed.). PLOS ONE. 2019 Sep 18; 14(9):
e0222178 . DOI: 10.1371/journal.pone.0222178 - van Riet E, Ainai A, Suzuki T, Hasegawa H. Mucosal IgA responses in influenza virus infections: Thoughts for vaccine design. Vaccine. 2012 Aug 31; 30(40): 5893–900. DOI: 10.1016/j.vaccine.2012.04.109
- Ainai A, Suzuki T, Tamura S, Hasegawa H. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate. Viral Immunol. 2017 Jul; 30(6): 451–62. DOI: 10.1089/vim.2017.0022
- Sano K, Ainai A, Suzuki T, Hasegawa H. Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics. Expert Rev Vaccines. 2018 Aug 3; 17(8): 687–96. DOI: 10.1080/14760584.2018.1507743
- Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI-C. Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies. J Infect Dis. 2018 Feb 14; 217(5): 731–41. DOI: 10.1093/infdis/jix632
- Nguyen VH, Vizzotti C, Uruena A, Giglio N, Magneres C, Richmond H. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina. Vaccine. 2020 Apr; 38(20): 3682–9. DOI: 10.1016/j.vaccine.2020.02.081
- Nichol KL, Goodman M. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine. 2002 May; 20: S21–4. DOI: 10.1016/S0264-410X(02)00124-X
- Gutiérrez JP, Bertozzi SM. Vacunación contra influenza para adultos mayores en México: consideraciones económicas. Salud Pública México. 2005 Jun; 47(3): 234–9. DOI: 10.1590/S0036-36342005000300007
- PAHO. EPI Newsletter: Expanded Program on Immunization in the Americas. 2004: 26(6): 2–4.
https://www.paho.org/hq/dmdocuments/2012/Influenza-Cost-Effectiveness-Costa-Rica.pdf (Accessed Jan 17, 2021). - Porras-Ramírez A, Alvis-Guzmán N, Rico-Mendoza A, Alvis-Estrada L, Castañeda-Orjuela CA, Velandia-González MP, et al. Costo efectividad de la vacunación contra influenza en menores de 2 años y mayores de 65 años en Colombia. Rev Salud Pública. 2009 Oct; 11(5): 689–99. DOI: 10.1590/S0124-00642009000500002
- Yue M, Dickens BL, Yoong JS, I-Cheng Chen M, Teerawattananon Y, Cook AR. Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study. Value Health. 2019 Dec; 22(12): 1345–54. DOI: 10.1016/j.jval.2019.07.001
- Fisman DN, Tuite AR. Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canada. Cowling BJ (ed.). PLoS ONE. 2011 Nov 14; 6(11): e27420. DOI: 10.1371/journal.pone.0027420
- Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? Vaccine. 2004 Dec; 23(5): 639–45. DOI: 10.1016/S0264-410X(04)00519-5
- Kosteneffectiviteit van influenzavaccinatie in Nederland|Nederlands Tijdschrift voor Geneeskunde.
https://www.ntvg.nl/artikelen/kosteneffectiviteit-van-influenzavaccinatie-nederland/volledig (Accessed Jan 17, 2021). - Mullooly JP. Influenza Vaccination Programs for Elderly Persons: Cost-Effectiveness in a Health Maintenance Organization. Ann Intern Med. 1994 Dec 15; 121(12): 947. DOI: 10.7326/0003-4819-121-12-199412150-00008
- Wang C-S, Wang S-T, Chou P. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine. 2002 Jun; 20(19–20): 2494–9. DOI: 10.1016/S0264-410X(02)00181-0
- Hoshi S-L, Kondo M, Honda Y, Okubo I. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan. Vaccine. 2007 Aug; 25(35): 6511–21. DOI: 10.1016/j.vaccine.2007.05.067
- Schooling CM, Wong LC, Chau J, Cheung A, Ho A, McGhee SM. Cost-effectiveness of influenza vaccination for elderly people living in the community. Hong Kong Med J Xianggang Yi Xue Za Zhi. 2009 Oct; 15(Suppl 6): 44–7.
- You JH, Ming W, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014 Dec; 14(1): 618. DOI: 10.1186/s12879-014-0618-9
- Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015 Jan; 33(5): 734–41. DOI: 10.1016/j.vaccine.2014.10.079
- Brydak L, Roiz J, Faivre P, Reygrobellet C. Implementing an Influenza Vaccination Programme for Adults Aged ≥65 Years in Poland: A Cost-Effectiveness Analysis. Clin Drug Investig. 2012 Feb; 32(2): 73–85. DOI: 10.2165/11594030-000000000-00000
- Van Bellinghen L-A, Meier G, Van Vlaenderen I. The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model. Ho PL (ed.). PLoS ONE. 2014 Jun 6; 9(6):
e98437 . DOI: 10.1371/journal.pone.0098437 - Duru G, Carrat F, Pribil C, Bricaire F, Pujol P, Robert J, et al. Cost Effectiveness of Quadrivalent Influenza Vaccine Over Trivalent Vaccine in France. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2014 Nov; 17(7): A678. DOI: 10.1016/j.jval.2014.08.2525
- Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, et al. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J Am Geriatr Soc. 2016 Oct; 64(10): 2126–31. DOI: 10.1111/jgs.14323
- Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Hum Vaccines Immunother. 2018 Jun 3; 14(6): 1331–41. DOI: 10.1080/21645515.2018.1438792
- Jamotte A, Clay E, Macabeo B, Caicedo A, Lopez JG, Bricks L, et al. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Hum Vaccines Immunother. 2017 Apr 3; 13(4): 877–88. DOI: 10.1080/21645515.2016.1256928
- Kim Y-K, Song JY, Jang H, Kim TH, Koo H, Varghese L, et al. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics. 2018 Dec; 36(12): 1475–90. DOI: 10.1007/s40273-018-0715-5
- Chen C, Liu GE, Wang MJ, Gao TF, Jia HP, Yang H, et al. Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population. Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Oct 6; 53(10): 993–9.
- Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, et al. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Vaccine. 2020 Jan; 38(5): 1057–64. DOI: 10.1016/j.vaccine.2019.11.045
- Yang J, Atkins KE, Feng L, Baguelin M, Wu P, Yan H, et al. Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis. BMC Med. 2020 Dec; 18(1): 90. DOI: 10.1186/s12916-020-01545-6
- Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. Value Health. 2007 Mar; 10(2): 98–116. DOI: 10.1111/j.1524-4733.2006.00157.x
- Newall AT, Scuffham PA, Kelly H, Harsley S, MacIntyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine. 2008 Apr; 26(17): 2142–53. DOI: 10.1016/j.vaccine.2008.01.050
- Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of people aged 50–64 years in Australia: results are inconclusive. Aust N Z J Public Health. 2011 Apr; 35(2): 180–6. DOI: 10.1111/j.1753-6405.2010.00639.x
- Aballea S, Dejuanes J, Barbieri M, Martin M, Chancellor J, Oyaguez I, et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: A model-based analysis for Spain. Vaccine. 2007 Sep 28; 25(39–40): 6900–10. DOI: 10.1016/j.vaccine.2007.07.033
- Choi EJ, Park JH, Chun BC. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea. Vaccine. 2020 Jul; 38(32): 5002–8. DOI: 10.1016/j.vaccine.2020.05.065
- Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine. 2006 Feb; 24(7): 1035–43. DOI: 10.1016/j.vaccine.2004.12.033
- Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza Vaccination. Am J Prev Med. 2006 Jul; 31(1): 72–9. DOI: 10.1016/j.amepre.2006.03.008
- Akın L, Macabéo B, Caliskan Z, Altinel S, Satman I. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in Turkey. Borrow R (ed.). PLOS ONE. 2016 Jun 20; 11(6):
e0157657 . DOI: 10.1371/journal.pone.0157657 - Yang J, Yan H, Feng LZ, Yu HJ. [Cost-effectiveness of potential government fully-funded influenza vaccination in population with diabetes in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2019 Oct 6; 53(10): 1000–6.
- Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan; 8(1): 30–41. DOI: 10.1038/nrcardio.2010.165
- Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes A-C, Millett ERC, et al. Temporal Trends and Patterns in Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals. JAMA Cardiol. 2019 Nov 1; 4(11): 1102. DOI: 10.1001/jamacardio.2019.3593
- Sribhutorn A, Phrommintikul A, Wongcharoen W, Chaikledkaew U, Eakanunkul S, Sukonthasarn A. Influenza vaccination in acute coronary syndromes patients in Thailand: The cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia. J Geriatr Cardiol JGC. 2018 Jun; 15(6): 413–21.
- Peasah SK, Meltzer MI, Vu M, Moulia DL, Bridges CB. Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US. Lazzeri C (ed.). PLOS ONE. 2019 Apr 29; 14(4):
e0213499 . DOI: 10.1371/journal.pone.0213499 - Suh J, Kim B, Yang Y, Suh D-C, Kim E. Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea. Vaccine. 2017 May; 35(21): 2811–7. DOI: 10.1016/j.vaccine.2017.04.016
- Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med. 2017 Dec; 15(1): 166. DOI: 10.1186/s12916-017-0932-3
- Blommaert A, Bilcke J, Vandendijck Y, Hanquet G, Hens N, Beutels P. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. Vaccine. 2014 Oct; 32(46): 6075–83. DOI: 10.1016/j.vaccine.2014.08.085
- García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. Hum Vaccines Immunother. 2016 Sep; 12(9): 2269–77. DOI: 10.1080/21645515.2016.1182275
- Nagy L, Heikkinen T, Sackeyfio A, Pitman R. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. PharmacoEconomics. 2016 Sep; 34(9): 939–51. DOI: 10.1007/s40273-016-0430-z
- Yang M-C, Tan EC-H, Su J-J. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Hum Vaccines Immunother. 2017 Jan 2; 13(1): 81–9. DOI: 10.1080/21645515.2016.1225636
- Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum Vaccines Immunother. 2018 Aug 3; 14(8): 1867–73. DOI: 10.1080/21645515.2018.1469368
- Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, et al. The Effectiveness of Vaccination against Influenza in Healthy, Working Adults. N Engl J Med. 1995 Oct 5; 333(14): 889–93. DOI: 10.1056/NEJM199510053331401
- Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D. Cost-Effectiveness of a Recommendation of Universal Mass Vaccination for Seasonal Influenza in the United States. Value Health. 2011 Sep; 14(6): 800–11. DOI: 10.1016/j.jval.2011.03.005
- Dabestani NM, Leidner AJ, Seiber EE, Kim H, Graitcer SB, Foppa IM, et al. A review of the cost-effectiveness of adult influenza vaccination and other preventive services. Prev Med. 2019 Sep; 126: 105734. DOI: 10.1016/j.ypmed.2019.05.022
- MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016 Dec 15; 102(24): 1953–6. DOI: 10.1136/heartjnl-2016-309983
- Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny M-P. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. Vaccine. 2018 Jun; 36(28): 3993–7. DOI: 10.1016/j.vaccine.2018.05.099
- Colrat F, Thommes E, Largeron N, Alvarez FP. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine. 2021 Mar 15; 39(Suppl 1): A42–A50. DOI: 10.1016/j.vaccine.2020.12.036
- Ropero-Álvarez AM, El Omeiri N, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic. Hum Vaccines Immunother. 2016 May 19; 12(8): 2206–14. DOI: 10.1080/21645515.2016.1157240
- Fica CA, Antunez RM, Cuevas AK, Rodriguez NA, Aravena RP. Prescripción de la vacuna anti influenza por médicos institucionales y estudiantes de especialidades médicas en un hospital docente. Rev Chil Infectol. 2001; 18(1).
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182001000100003&lng=en&nrm=iso&tlng=en . DOI: 10.4067/S0716-10182001000100003 - Hershey CO, Karuza J. Delivery of Vaccines to Adults: Correlations with Physician Knowledge and Patient Variables. Am J Med Qual. 1997 Sep; 12(3): 143–50. DOI: 10.1177/106286069701200302
- Baron G, De Wals P, Milord F. Vaccination practices of Quebec family physicians. Influenza vaccination status and professional practices for influenza vaccination. Can Fam Physician Med Fam Can. 2001 Nov; 47: 2261–6.
- Olasupo OO, Brown J, Segal R. Missed Opportunities for Influenza and Pneumococcal Vaccinations in the Elderly in the US – A Cross-Sectional Analysis. Value Health. 2018 May 1; 21: S158. DOI: 10.1016/j.jval.2018.04.1083
- Davis BM, Black D. Identifying the Challenges to Adult Influenza Vaccination in Latin America. Value Health. 2017 Oct 1; 20(9): A934. DOI: 10.1016/j.jval.2017.08.2951
- Zimmerman RK, Santibanez TA, Janosky JE, Fine MJ, Raymund M, Wilson SA, et al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med. 2003 Jan; 114(1): 31–8. DOI: 10.1016/S0002-9343(02)01421-3
- Centers for Disease Control and Prevention (CDC). Reasons reported by Medicare beneficiaries for not receiving influenza and pneumococcal vaccinations—United States, 1996. MMWR Morb Mortal Wkly Rep. 1999 Oct 8; 48(39): 886–90.
- Centers for Disease Control (CDC). Adult immunization: Knowledge, attitudes, and practices—DeKalb and Fulton Counties, Georgia, 1988. MMWR Morb Mortal Wkly Rep. 1988 Nov 4; 37(43): 657–61.
- Bovier PA, Chamot E, Bouvier Gallacchi M, Loutan L. Importance of patients’ perceptions and general practitioners’ recommendations in understanding missed opportunities for immunisations in Swiss adults. Vaccine. 2001 Sep; 19(32): 4760–7. DOI: 10.1016/S0264-410X(01)00223-7
- Srivanichakom W, Asavathitanonta K, Washirasaksiri C, Chaisathaphon T, Chouriyagune C, Phisalprapa P, et al. Prescribing rate of influenza vaccine among internal medicine residents for outpatient continuum care. J Med Assoc Thail Chotmaihet Thangphaet. 2014 Dec; 97(12): 1281–9.
- Jaiyeoba O, Villers M, Soper DE, Korte J, Salgado CD. Association between health care workers’ knowledge of influenza vaccine and vaccine uptake. Am J Infect Control. 2014 Jan; 42(1): 69–70. DOI: 10.1016/j.ajic.2013.06.020
- Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, et al. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016 Oct; 12: 295–301. DOI: 10.1016/j.ebiom.2016.08.042
- Bertoldo G, Pesce A, Pepe A, Pelullo CP, Di Giuseppe G, The Collaborative Working Group. Seasonal influenza: Knowledge, attitude and vaccine uptake among adults with chronic conditions in Italy. Manzoli L (ed.). PLOS ONE. 2019 May 1; 14(5):
e0215978 . DOI: 10.1371/journal.pone.0215978 - Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of Influenza Vaccination Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 – 2016. Cowling BJ (ed.). PLOS ONE. 2017 Jan 26; 12(1):
e0170550 . DOI: 10.1371/journal.pone.0170550 - Sosa Liprandi Á, Zaidel EJ, Lopez Santi R, Araujo JJ, Baños González MA, Busso JM, et al. Influenza and Pneumococcal Vaccination in Non-Infected Cardiometabolic Patients from the Americas during the COVID-19 Pandemic. A Sub-Analysis of the CorCOVID-LATAM Study. Vaccines. 2021 Feb 4; 9(2). DOI: 10.3390/vaccines9020123
- Burki T. Vaccine misinformation and social media. Lancet Digit Health. 2019 Oct; 1(6): e258–9. DOI: 10.1016/S2589-7500(19)30136-0
- Medical Misinformation. Vet the Message! Int J Cardiol. 2019 Feb; 277: 1–2. DOI: 10.1016/j.ijcard.2018.12.071
- Waszak PM, Kasprzycka-Waszak W, Kubanek A. The spread of medical fake news in social media – The pilot quantitative study. Health Policy Technol. 2018 Jun; 7(2): 115–8. DOI: 10.1016/j.hlpt.2018.03.002
- Chan M-PS, Jamieson KH, Albarracin D. Prospective associations of regional social media messages with attitudes and actual vaccination: A big data and survey study of the influenza vaccine in the United States. Vaccine. 2020 Sep 11; 38(40): 6236–47. DOI: 10.1016/j.vaccine.2020.07.054
- Guidry JPD, Coman IA, Vraga EK, O’Donnell NH, Sreepada N. (S)pin the flu vaccine: Recipes for concern. Vaccine. 2020 Jul 22; 38(34): 5498–506. DOI: 10.1016/j.vaccine.2020.06.012
- Pulido C, Ruiz-Eugenio L, Redondo-Sama G, Villarejo-Carballido B. A New Application of Social Impact in Social Media for Overcoming Fake News in Health. Int J Environ Res Public Health. 2020 Apr 3; 17(7): 2430. DOI: 10.3390/ijerph17072430
- Trethewey SP. Strategies to combat medical misinformation on social media. Postgrad Med J. 2020 Jan; 96(1131): 4–6. DOI: 10.1136/postgradmedj-2019-137201
- Steffens MS, Dunn AG, Wiley KE, Leask J. How organisations promoting vaccination respond to misinformation on social media: A qualitative investigation. BMC Public Health. 2019 Dec; 19(1): 1348. DOI: 10.1186/s12889-019-7659-3
- YouTube, Facebook and Twitter align to fight Covid vaccine conspiracies. BBC News. 2020 Nov 20.
https://www.bbc.com/news/technology-55005385 (Accessed Mar 26, 2021). - Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5306a1.htm (Accessed Jan 17, 2021). - Vizzotti C, Katz N, Stecher D, Aquino A, Juárez MDV, Urueña A. Assessment of the use in adults of four vaccines: A population survey in Argentina. Medicina (Mex). 2018; 78(2): 76–82.
- Galante M, Konfino J, Ondarsuhu D, Goldberg L, O’Donnell V, Begue G, et al. Principales resultados de la Tercera Encuesta Nacional de Factores de Riesgo de Enfermedades No Transmisibles en Argentina. Rev Argent Salud Pública. 2019 Jan 25; 6.
- SI-PNI Web.
http://sipni.datasus.gov.br/si-pni-web/faces/inicio.jsf (Accessed Jan 17, 2021). - Jarvis JD, Woods H, Bali A, Oronsaye E, Persaud N. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists. Daivadanam M (ed.). PLOS ONE. 2019 Aug 9; 14(8):
e0220781 . DOI: 10.1371/journal.pone.0220781 - EMLs Around The World.
https://global.essentialmeds.org/dashboard/medicines/964 (Accessed Jan 17, 2021). - PAHO|Fondo Rotatorio.
https://www.paho.org/hq/index.php?option=com_topics&view=article&id=396&Itemid=42192&lang=es (Accessed Jan 17, 2021). - Gopal S, Davis MM. Delivery of influenza vaccine to non-elderly persons with cardiovascular disease, with varying national supply of vaccine: A decision analysis. Hum Vaccin. 2005 Dec; 1(6): 217–23. DOI: 10.4161/hv.1.6.2225
- Nowalk MP, Zimmerman RK, Shen S, Jewell IK, Raymund M. Barriers to pneumococcal and influenza vaccination in older community-dwelling adults (2000–2001). J Am Geriatr Soc. 2004 Jan; 52(1): 25–30. DOI: 10.1111/j.1532-5415.2004.52006.x
- Chi R-C, Neuzil KM. The association of sociodemographic factors and patient attitudes on influenza vaccination rates in older persons. Am J Med Sci. 2004 Mar; 327(3): 113–7. DOI: 10.1097/00000441-200403000-00001
- Villarreal R, Zaidel EJ, Cestari HG, Mele EF, Sosa Liprandi MI, Sosa Liprandi A. Influenza and Pneumococcal Vaccination in Patients with Cardiovascular Disease: Pilot Project. Rev Argent Cardiol. 2016; 84: 582–583.
- Changing the Conversation on Adult Influenza Vaccination – Vaccines 4 Life.
https://www.vaccines4life.com/changing-the-conversation/ (Accessed Jan 17, 2021).
DOI: https://doi.org/10.5334/gh.1069 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jun 23, 2021
Accepted on: Jun 23, 2021
Published on: Aug 5, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2021 Álvaro Sosa Liprandi, María Inés Sosa Liprandi, Ezequiel José Zaidel, Gabriel M. Aisenberg, Adrián Baranchuk, Eduardo Costa Duarte Barbosa, Gabriela Borrayo Sánchez, Bryce Alexander, Fernando Tomás Lanas Zanetti, Ricardo López Santi, Ana Girleza Múnera-Echeverri, Pablo Perel, Daniel Piskorz, Carlos Enrique Ruiz-Mori, Jorge Saucedo, Osiris Valdez, José Ramón González Juanatey, Daniel José Piñeiro, Fausto J. Pinto, Fernando Stuardo Wyss Quintana, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.